Myriad Genetics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Myriad Genetics, Inc.
Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
October’s approvals include the US FDA approval of Myriad’s myChoice CDx companion diagnostic for GlaxoSmithKline’s ovarian cancer drug and the approval or Medtronic’s Valiant Navion thoracic stent graft system in Japan.
Japan grants first approval worldwide for Daiichi Sankyo's oral FLT3 inhibitor, marking progress for Japanese firm's global oncology ambitions.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Other Names / Subsidiaries
- Assurex Health
- Counsyl, Inc.
- Crescendo Bioscience
- Myriad Genetic Laboratories, Inc.
- Myriad Pharmaceuticals
- Myriad RBM
- Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG
- Rules Based Medicine
- Sividon Diagnostics